SUMMARY

The Internal Medicine Division continues to provide most of the hospital's functions caring for more than 150 in-patients on a daily basis outside the Clinical Teaching Units. In spite of the many obligations, our division is one of the most accomplished in research with four of our members devoting more than 50% of their time in highly productive research activities.

1. Research and Publications:


Secured grants for the Internal Medicine Division for their research are: Dr. John Hoffer $111,030.00 for his research in Vitamin C & D treatment, Dr. Susan Kahn received $607,438.00 for her research in Thrombosis, Dr. Vicky Tagalakis received $167,700.00 for her research in Epidemiology & Venous Thrombosis, Dr. Schiffrin received $918,224.00 for his research in hypertension, heart and stroke disease.

2. Teaching and learning (undergraduate and graduate)

Teaching Activities:

Clinical Teaching Unit: 4 weeks/year, Staff: 10, Residents: 6, Students: 2; Drs. R. Becker, R. Bunea, M. Elizov, J. Raffoul, L. Trudeau, V. Tagalakis, B. Cummings, S. Kahn, Ambulatory Internal Medicine Clinics: 4 clinics/week, Staff: 10, Residents 20-25, Students: 8 Drs. R. Becker, R. Bunea, M. Elizov, B. Cummings, S. Kahn, J. Raffoul, L. Trudeau, V. Tagalakis, J. Hoffer, J. Lipes
Consult Service: 7 day/wk, Staff: 6, Residents: 1, Fellows: 1; Drs. B. Cummings, M. Elizov, R. Bunea, J. Raffoul, L. Trudeau, V. Tagalakis
Emergency Room/Medical Short Stay Unit: 7 day/wk, Staff: 6, Residents: 6, Students: 4; Drs. R. Becker, R. Bunea, M. Elizov, B. Cummings, J. Raffoul, L. Trudeau, V. Tagalakis
Core Lectures: 10 hrs/year, Staff: 6, Residents: 20-30; Drs. R. Becker, R. Bunea, M. Elizov, B. Cummings, S. Kahn, J. Raffoul, L. Trudeau, V. Tagalakis, J. Hoffer
Orals & Exams: 11 hrs/year Students: 16-20; Drs. R. Becker, R. Bunea, M. Elizov, B. Cummings, S. Kahn, J. Raffoul, L. Trudeau, V. Tagalakis, J. Hoffer
Professional Skills Tutorial Group: 48 hrs/year, Students: 16-20; Drs. M. Elizov, B. Cummings
Clinical Activities:

Emergency Room/Medical Short Stay Unit/Consults: 8 weeks/yr: Drs. R. Becker, R. Bunea, M. Elizov, J. Raffoul, V. Tagalakis, L. Trudeau

Emergency Room/Medical Short Stay Unit/Consults: 2 weeks/yr: Drs. B. Cummings, S. Kahn

Nutritional Support Team Consultation: 16-20 weeks/year: Dr. J. Hoffer

Internal Medicine Out-Patient Residents Clinic: ½ clinic/week: Drs. R. Becker, R. Bunea, M. Elizov, J. Raffoul, V. Tagalakis, J. Hoffer, B. Cummings, L. Trudeau, B. Cummings, J. Lipes

Cardiovascular Prevention Center: 2 clinic/wk: Drs. E. Schiffrin, L. Trudeau

Resident’s Hypertension Clinic: 2 clinic/wk: Drs. R. Becker, R. Bunea, M. Elizov, J. Raffoul, V. Tagalakis, J. Hoffer, L. Trudeau, B. Cummings, B. Cummings

Thrombosis Clinic: 2 day clinic per week, Drs. S. Kahn, V. Tagalakis

Pre-Operative Clinic: 1 ½ days per week: Drs. B. Cummings

3. Involvement in the community:

Hoffer, LJ

McGill
Nutrition pearls for surgeons, Jewish General Hospital Surgical Rounds, March 1, 2012
How much vitamin D is enough? How much is Dangerous?, Internal Medicine Academic Rounds, Jewish General Hospital, March 8, 2012

National
Appropriate protein provisions in critical illness. Emerging strategies in optimizing Nutrition therapy Deliver, Nestle Health Science Seminar, Toronto, ON, November 2, 2012

Kahn, SR

McGill
Preventing VTE in medical and surgical patients. McGill Division of Internal Medicine Rounds. October 9, 2012.
Maximizing benefit and minimizing harm: Development and validation of a clinical prediction rule for recurrent venous thromboembolism. Lady Davis Institute Principal Investigator Rounds, Jewish General Hospital. April 18, 2012.

National

International
Incidence and risk factors of PTS. 16th European Vascular Course. Maastricht, the Netherlands, March 11-13, 2012.

Schiffrin, EL

McGill
New developments in hypertension. Medical Grand Rounds, McGill University Hospital Center, Montreal, PQ, January 24, 2012.
National
Refractory hypertension, Invited Lecture at the Annual Meeting of the Quebec Hypertension Society, Quebec City, PQ, January 20, 2012.

International
Aldosterone effects on the vasculature, 13th Richard Underwood Memorial Lecture, Endocrine Grand Rounds, Brigham and Women’s Hospital/Beth Israel Deaconess Hospital/Department of Medicine, Harvard Medical School, Boston, MA, January 31, 2012.
Resistant hypertension, Lecture as “Speaker of the Year 2012”, Belgium, March 5, 2012, Universitair Zikenhuis Gent, Department of Cardiology (Prof. Tine De Backer).
Vascular remodeling in chronic kidney disease, Lecture as “Speaker of the Year 2012”, Belgium, March 6, 2012, Cliniques Universitaires St-Luc, Université Catholique de Bruxelles (Prof. Alexandre Persu).
Resistant hypertension, Lecture as “Speaker of the Year 2012”, Belgium, March 7, 2012, Université de Liège, départements d’endocrinologie, cardiologie et néphrologie (Prof. Jean-Marie Krzesinski).
Immunity and inflammation in hypertension, Lecture as “Speaker of the Year 2012”, Belgium, March 8, 2012, Universitair Aiekenhuis Antwerpen (Prof. Hilde Heuten).
BP in 2012 and resistant hypertension, Medical Grand Rounds at University of Virginia Medical Center Department of Medicine, Charlottesville, VA, September 5, 2012.
Immunity and hypertension, Research Seminar at University of Virginia Medical Center Cardiovascular Research Centre, Charlottesville, VA, September 6, 2012.

Tagalakis, V

McGill
National
Tagalakis V, Blostein M, Emed J, Kahn S. Lots about clots and cancer: What cancer patients and their families should know about deep vein thrombosis and pulmonary embolism. Oral presentation at: CIHR Café Scientifique; 2012 March 29th; Montreal, Canada.

International

4. Partnerships: None to report

5. Honours, awards, and prizes:
The Division of Internal Medicine members have received career awards and or honors of recognition towards their research. Dr. Elizov received $29,000.00 for here research in Mentorship in Clinic Medicine. She also received the 2012-2013 Richard and Sylvia Cruess Faculty Scholar in Medical Education. Dr. John Leonard Hoffer was awarded the 2012 Kursheed Jeejeebhoy Award and Plenary Lecture, Canadian Nutrition Society. Vicky Tagalakis was awarded $12,000.00 for Epidemiology of venous thrombosis and pharmacoepidemiology, Department of Medicine, JGH

6. Milestones:
Dr. Jed Lipes has joined the Jewish General Hospital in the Division of General Internal Medicine and the Department of Adult Critical Care. He obtained dual specialty training in both general internal medicine and critical care medicine at McGill University. He completed additional subspecialty training in cardiovascular critical care at the Institut universitaire de cardiologie et de pneumologie de Québec. He then returned to Montreal to pursue a fellowship in advanced echocardiography at the Jewish General Hospital. His research interests include echocardiography in critical care, mechanical ventilation and quality improvement.

7. Fundraising: None to report.

SECTION 1 – DIVISION STATUS

1. Mission and objectives of the Division
The Division of Internal Medicine will continue to enhance McGill University in their role as one of Quebec’s leading teaching institutions. Our Division fulfills its role in achieving high standards in all aspects of academic medicine. All physicians in the Division have a clear academic role. Recruitment is the most important priority as the burden of clinical service has become increasingly higher over the years

2. A nominative list of academic staff, their academic rank

- Dr. Rubin Becker, Chief, Division of Internal Medicine, Jewish General Hospital; Medical Director, Mount Sinai; Chief of Medicine, Jewish
Dr. Ruxandra Bunea, Director, Postgraduate Education, Jewish General Hospital; Assistant Professor McGill University

Dr. Vicky Tagalakis: Research Director, Department of Medicine, Jewish General Hospital, Program Director for Internal Medicine Fellowship Training Program and Associate Professor, McGill University

Dr. Susan Kahn: Director, Thrombosis Clinic, Jewish General Hospital; Associate Co-Director, Lady Davis Institute for Medical Research; Professor of Medicine, McGill University

Dr. Beth Cummings: Director, Undergraduate Medical Education, Jewish General Hospital; Clerkship Program Chair and Assistant Professor, McGill University

Dr. Ernesto Schiffrin: Physician-in-Chief and Director of the Cardiovascular Prevention Centre, Jewish General Hospital; Canada Research Chair in Hypertension and Vascular Research, Lady Davis Institute for Medical Research; Professor and Vice-Chair (Research), Department of Medicine, McGill University.

Dr. Joseph Raffoul: CTU Director and Medical Gatekeeper Jewish General Hospital; Assistant Professor of Medicine, McGill University

Dr. John Leonard Hoffer: Professor of Medicine, McGill University

Dr. Michelle Elizov: McGill Representative, Board of Directors, Canadian Association of Medical Education; Director of Medical Education Elective Program and Co-Director of Medical Education Fellowship Program, Centre for Medical Education, and Associate Professor of Medicine, McGill University

Dr. Luc Trudeau: Assistant Professor, McGill University

Dr. Harvey Chang: Assistant Professor, McGill University

Dr. Jed Lipes: Assistant Professor, McGill University

SECTION II – PUBLICATIONS, AND SERVICES OUTSIDE MCGILL

1. Grants and awards received

Research, Grants & Awards: See Annex 1

2. Scholarly works published in the 2012 calendar year:

Kahn, Susan


Lipes, Jed


Schiffrin, Ernesto L.


--Kasal DAB, Schiffrin EL. Angiotensin II, aldosterone and anti-inflammatory


Tagalakis, Vicky


Trudeau, Luc

--**Trudeau, L** The SPS3 Investigators, Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke, NEJM, 2012, Vol. 367 (9), 817-825 (peer reviewed)

--**Trudeau, L** Société québécoise d’hypertension artérielle, Guide thérapeutique, 4ième édition, Trudeau, L, Chapitre 27, L’hypertension artérielle et les produits de santé naturels, 2012 (peer-reviewed)

3. **Academic and community engagement service outside of McGill by individual members of the unit: see above under Community Involvement**

**SECTION III – CONFIDENTIAL INFORMATION**

1. **Consulting activities:**

<table>
<thead>
<tr>
<th>Name of Faculty Member</th>
<th>Private Sector Consulting # of days</th>
<th>Public Sector Consulting # of days</th>
<th>Other number of Days</th>
<th>Number of Total Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. R. Becker</td>
<td></td>
<td>Internal Medicine Consults for Jewish Rehabilitation Hospital - 1 day/week</td>
<td></td>
<td>52</td>
</tr>
<tr>
<td>Dr. R. Becker</td>
<td></td>
<td>Mount Sinai Hospital - ½ day/week</td>
<td></td>
<td>26</td>
</tr>
<tr>
<td>Dr. J. Raffoul</td>
<td></td>
<td>Internal Medicine Consults Lakeshore General Hospital, 2 evening/month</td>
<td></td>
<td>24</td>
</tr>
<tr>
<td>Dr. J. Raffoul</td>
<td></td>
<td>Brunswick Medical Center -1 day/Month</td>
<td></td>
<td>12</td>
</tr>
<tr>
<td>Dr. L. Trudeau</td>
<td></td>
<td>Institut de Réadaptation - 1 day/month</td>
<td></td>
<td>12</td>
</tr>
</tbody>
</table>

Respectfully Submitted

Rubin Becker, MD
Chief, Division of Internal Medicine
## Annex 1: Research, Grants & Awards

<table>
<thead>
<tr>
<th>NAME</th>
<th>AGENCY</th>
<th>TITLE</th>
<th>External Grants</th>
<th>Career Awards</th>
<th>Industrial Contracts</th>
<th>Clinical Research Awards</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elizov, M.</td>
<td>Department of Medicine. JGH</td>
<td>Mentorship in Clinical Medicine</td>
<td>12,000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hoffer, Leonard J.</td>
<td>Université McGill</td>
<td>Vitamind therapy in JGH patients</td>
<td>2,834</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hoffer, Leonard J.</td>
<td>Lotte &amp; John Hecht Memorial Foundation</td>
<td>Study - Intravenous Vitamin C in combination with chemo therapy in lung cancer patients.</td>
<td>100,000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hoffer, Leonard J.</td>
<td>Immunotec Recherche</td>
<td>Method development to measure plasma amino acids and reduced total cysteine.</td>
<td>8,196</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kahn, Susan Rebecca</td>
<td>Institut de Recherche en Sante du Canada</td>
<td>TIPPS (Thrombophilia in pregnancy prophylaxis study): A multicentre, multinational randomized control trial of prophylactic low molecular weight heparin (LMWH) in high risk pregnant thrombophilic women. CIHR 524E-CVD-91 01-004</td>
<td>1,800</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kahn, Susan Rebecca</td>
<td>Heart and Stroke Foundation of Ontario (HSFO)</td>
<td>NA677T-Recurrent venous thromboembolism risk stratification evaluation (REVERSE) long term follow-up to define if lifelong anticoagulation is required In high risk patients with a first unprovoked venous thromboembolism.</td>
<td>3,466</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kahn, Susan Rebecca</td>
<td>Institut de Recherche en Sante du Canada</td>
<td>GENEVTE: Gene Interactions and Recurrent Venous Thromboembolism.</td>
<td>3,750</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kahn, Susan Rebecca</td>
<td>Fondation des Maladies du Cœur de l’Ontario</td>
<td>P. Wells - HSFO - Development and validation of clinical prediction rules for bleeding for patients on anticoagulant therapy for venous thromboembolism.</td>
<td>6,750</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kahn, Susan Rebecca</td>
<td>Institut de Recherche en Sante du Canada</td>
<td>Step Monitoring to Improve ARTERial health (SMARTER).</td>
<td>9,317</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kahn, Susan Rebecca</td>
<td>Regroupement de particuliers</td>
<td>Thrombosis Clinic.</td>
<td>13,200</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kahn, Susan Rebecca</td>
<td>National Institutes of Health</td>
<td>Pharmacomechanical catheter-directed thrombolysis for acute DVT-attract trial.</td>
<td>20,248</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kahn, Susan Rebecca</td>
<td>Institut de Recherche en Sante du Canada</td>
<td>A Pilot Study Assessing Feasibility of a Randomized, Placebo- controlled Trial of Low-Molecular-Weight-Heparin for Postpartum Prophylaxis in Women at Risk of Developing Venous Thromboembolism (pilot PROSPER Trial)</td>
<td>25,291</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kahn, Susan Rebecca</td>
<td>Institut de Recherche en Sante du Canada</td>
<td>Furthering innovation in thrombosis research. - TRUST</td>
<td>25,741</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kahn, Susan Rebecca</td>
<td>Institut de Recherche en Sante du Canada</td>
<td>Randomized controlled trial of anticoagulation vs. placebo for a first symptomatic isolated distal deep-vein thrombosis (IDDVT) The CACTUS-PTS Trial.</td>
<td>31,543</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kahn, Susan Rebecca</td>
<td>Institut de Recherche en Sante du Canada</td>
<td>A randomized, placebo-controlled trial of compression stockings to prevent the post-thrombotic syndrome: The SOX</td>
<td>120,091</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kahn, Susan Rebecca</td>
<td>Fondation des Maladies du Cœur du Canada</td>
<td>Recherche épidémiologique sur les maladies thromboemboliques: conséquences et mécanismes</td>
<td>139,358</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kahn, Susan Rebecca</td>
<td>Fondation des Maladies du Cœur du Canada</td>
<td>Recherche épidémiologique sur les maladies thromboemboliques: conséquences et mécanismes</td>
<td>10,659</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kahn, Susan Rebecca</td>
<td>Sanofi-Aventis (Canada)</td>
<td>Thrombosis Fellowship.</td>
<td>37,671</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kahn, Susan Rebecca</td>
<td>Aventis Pharma</td>
<td>A double-blind, placebo-controlled, parallel, multicenter study on extended VTE prophylaxis in acutely III medical patients with prolonged immobilization.</td>
<td>6,000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kahn, Susan Rebecca</td>
<td>Lawson Health Research Institute</td>
<td>A prospective study of upper extremity deep vein thrombosis to determine the prevalence of post-thrombotic syndrome in patients managed with anticoagulation.</td>
<td>1,800</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kahn, Susan Rebecca</td>
<td>Quantiles Canada Inc.</td>
<td>A phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of (LMW) Heparin/Edoxaban versus (LMW) Heparin/Warfarin in subjects with symptomatic deep-vein</td>
<td>23,276</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kahn, Susan Rebecca</td>
<td>Boehringer Ingelheim (Canada) Ltd</td>
<td>1160.46 - A phase III, Randomized, double blind. parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute symptomatic venous</td>
<td>61,050</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schiffin, Ernesto</td>
<td>Fondation des Maladies du Coeur du Canada (FMCC)</td>
<td>Remodelage des artères de petit et gros calibre dans l'insuffisance rénale chronique.</td>
<td>8,078</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NAME</td>
<td>AGENCY</td>
<td>TITLE</td>
<td>External Grants</td>
<td>Career Awards</td>
<td>Industrial Contracts</td>
<td>Clinical Research Awards</td>
</tr>
<tr>
<td>-----------------------</td>
<td>---------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>-----------------</td>
<td>---------------</td>
<td>----------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Schiffrin, Ernesto</td>
<td>Fondation des Maladies du Cœur du Canada (FMCC)</td>
<td>Remodelage des artères de petit et gros calibre dans l'insuffisance rénale chronique.</td>
<td>9,890</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schiffrin, Ernesto</td>
<td>University of Barcelona</td>
<td>Dr. Cristina Sierra - Paid Permit from the Hospital Clinic of Barcelona in Spain</td>
<td>12,139</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schiffrin, Ernesto</td>
<td>Kao Corporation (Japan)</td>
<td>Research on vascular disease in hypertension: Role of endothelin, PPARs and T-lymphocytes.</td>
<td>40,000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schiffrin, Ernesto</td>
<td>Secrétariat des Chaires de Recherche du Canada</td>
<td>Remodeling of blood vessels in hypertension.</td>
<td>48,863</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schiffrin, Ernesto</td>
<td>Secrétariat des Chaires de Recherche du Canada</td>
<td>Remodeling of blood vessels in hypertension.</td>
<td>150,549</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schiffrin, Ernesto</td>
<td>Regroupement de Particuliers</td>
<td>Cardio hypertension research &quot;Fonds d'urgence&quot;</td>
<td>684</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schiffrin, Ernesto</td>
<td>Institut de Recherche en Santé du Canada</td>
<td>Congenital nephrone deficit and essential hypertension.</td>
<td>56,444</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schiffrin, Ernesto</td>
<td>Juvenile Diabetes Research Foundation</td>
<td>Nox-derived Rox: renal and vascular complications of type 1 Diabetes.</td>
<td>73,769</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schiffrin, Ernesto</td>
<td>Institut de Recherche en Santé du Canada</td>
<td>Vascular remodeling in hypertension: From genes to mice to humans.</td>
<td>112,147</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schiffrin, Ernesto</td>
<td>Institut de Recherche en Santé du Canada</td>
<td>T-regulatory cells and vascular injury in hypertension.</td>
<td>156,659</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schiffrin, Ernesto</td>
<td>Institut de Recherche en Santé du Canada</td>
<td>Endothelin, vascular inflammation and injury, and hypertension.</td>
<td>159,344</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schiffrin, Ernesto</td>
<td>Kao Corporation (Japan)</td>
<td>Research on vascular disease in hypertension: Role of endothelin, PPARs and T-lymphocytes.</td>
<td>10,016</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schiffrin, Ernesto</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>A double-blind, randomized, parallel design study to compare the effectiveness of Aliskiren versus Hydrochlorothiazide in mild- to moderate hypertensive type II diabetes mellitus patients in reversing the re-modeling of resistance arteries an correcting</td>
<td>25,491</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tagalakis, Vicky</td>
<td>Instituts de Recherche en Santé du Canada</td>
<td>Lots about clots and cancer: what cancer patients and their families should know about deep vein thrombosis and pulmonary embolism</td>
<td>3,000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tagalakis, Vicky</td>
<td>Fondation des Maladies du Cœur du Québec</td>
<td>Screening for previously undiagnosed malignancy in patients with unprovoked controlled trial using comprehensive computed tomography of venous thromboembolism: a randomized the abdomen/pelvis</td>
<td>4,845</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tagalakis, Vicky</td>
<td>Fondation des Maladies du Cœur du Québec</td>
<td>Screening for previously undiagnosed malignancy in patients with unprovoked controlled trial using comprehensive computed tomography of venous thromboembolism: a randomized the abdomen/pelvis</td>
<td>12,055</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tagalakis, Vicky</td>
<td>Fondation des Maladies du Cœur du Québec</td>
<td>Recherche épidémiologique et pharmaco-épidémiologique en thrombose veineuse</td>
<td>8,562</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tagalakis, Vicky</td>
<td>Fonds de la Recherche en Santé du Québec</td>
<td>Recherche épidémiologique et pharmaco-épidémiologique en thrombose veineuse</td>
<td>26,666</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tagalakis, Vicky</td>
<td>Pfizer Canada Inc.</td>
<td>Post-operative venous thromboembolism in patients with cancer A population based cohort study (WS5462014)</td>
<td>10,000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tagalakis, Vicky</td>
<td>Sanofi-Aventis (Canada)</td>
<td>Determining the timing of venous thromboembolism in the post-operative setting: a population-based cohort study.</td>
<td>29,354</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tagalakis, Vicky</td>
<td>Eisai Research Institute</td>
<td>FRAG-A001-401 - Dalteparin sodium injection (FRAGMIN): Multi-center. Open label, single-arm, controlled long-term (52 weeks) study for understanding safety and efficacy in subjects with malignancies and symptomatic venous Thrombosis</td>
<td>36,118</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tagalakis, Vicky</td>
<td>Department of Medicine. JGH</td>
<td>Epidemiology of venous thrombosis and pharmacoepidemiology</td>
<td>12,000</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>